Nigerian pharmacist Muhammad Kabir Musa blends bedside practice, research, and policy advocacy to reduce prescription errors and strengthen health systems in Nigeria and beyond.

Pharmacists have long been cast as back-room alchemists and front-counter “pill counters”—makers of medicines, managers of bottles and labels, the steady hands that keep health systems moving. Yet, in much of the world, the profession has been expanding into something far broader: medication management, patient counseling, and central roles in chronic disease care. It’s into this broader frame that Muhammad Kabir Musa has built his career—not only dispensing medicine, but also helping to show how a pharmacist can be a scientist, a systems thinker, and a policy voice with real-world impact.

Born and raised in Nigeria, Dr. Musa has carried his work from West Africa to Central Asia and North America. He has moved from bedside care to leadership and research, contributing to science with tangible, systems-level effects—shaping practice and policy locally and internationally.

From modest beginnings to academic milestones

Musa’s trajectory is a study in talent meeting opportunity. He began his schooling in Senrukperu—known locally as Okuta—in Baruten Local Government of Kwara State, Nigeria. He went on to Usmanu Danfodiyo University, earning a Bachelor of Pharmacy in October 2017. The following year, he was inducted by the Pharmacy Council of Nigeria, a milestone that signaled both intellectual mastery and professional readiness, placing his name in the nation’s pharmacists’ registry.

Real-world pressures followed quickly. During his mandatory internship at Ahmadu Bello University Teaching Hospital (ABUTH), he worked alongside clinicians on busy wards. He then entered Nigeria’s National Youth Service Corps, serving first in Lagos State and later in Kaduna. The Ministry of Health and Human Services posted him to the Pharmacy Department of General Hospital, Hunkuyi, where he handled the full spectrum of community-hospital responsibilities. All the while, he pushed forward academically—gaining admission to postgraduate study in Pharmaceutics and Industrial Pharmacy at Ahmadu Bello University, Zaria.

Curiosity about the science beneath better care drove his early research. In his department, he turned to nanotechnology-enabled drug delivery and chronopharmaceutical tablets—medicines designed to sync with the body’s rhythms. “Specifically, I focused on creating delayed-release tablets that follow circadian rhythms in the release of the active ingredient for antihypertensive patients to improve adherence and minimize side effects.” That line of inquiry produced his first review—with a colleague—in the International Journal of Pharmaceutical Research and Analysis, “Status of Oral Chronopharmaceuticals Drug Delivery System, Latest Technologies, and Hurdles.”

“In the review, I discovered that chronotherapeutics have the potential to optimize medication release with the body’s natural rhythms. However, current drug delivery technologies struggle to realize their potential fully. In the study, I demonstrated that more research and collaboration are critical in actualizing this technology,” he told me.

Turning to nanotechnology

In 2021, as COVID-19 stressed health systems and supply chains, Musa and his colleagues asked how to deploy reliable, low-cost tools fast. “We explored the promising applications of nanotechnology in the paper titled ‘Innovative Nanotechnology a Boon for Fight Against Pandemic COVID–19,’ we highlighted the critical role of nanotechnology in developing affordable, reliable diagnostics.” The study argued that “nanosensors would be appropriate for early diagnosis, while nanoscale fibres will improve personal protective equipment, both of which offer medical and economic benefits in terms of pandemics like COVID-19,” published in the Frontiers journal.

He pressed further in “Clinical Features, Treatment Approaches, and Promising Contributions of Nanomedicines Towards Covid-19,” published in the International Journal of Pharmaceutical Sciences and Research. The work examines clinical features and virulence mechanisms that are crucial for designing both pharmacological and non-pharmacological strategies. At a moment when clinical trials were advancing for “Moderna, Pfizer/BioNTech, Oxford/AstraZeneca, Sputnik V, and Sinopharm vaccines,” Musa and colleagues proposed using nanomedicine for targeted drug delivery and complementary chemotherapeutic strategies. The through-line was translational: take laboratory promise and focus it on outcomes and patient care.

Advancing health systems

After national service, Musa returned to ABUTH in Shika, Zaria, as a tenured clinical pharmacist. He rose from the bedside to the Pharmacy Department’s Quality Control laboratory, where he worked with chemists, microbiologists, and senior colleagues to oversee assurance protocols and scientific communications. His remit included upholding standards of pharmaceutical care—from screening medicines in use to flagging substandard products to hospital leadership and reporting them to the National Agency for Food and Drug Administration and Control (NAFDAC).

In 2022, his cross-border trajectory accelerated with a fully funded scholarship for a Master’s degree in public health at Nazarbayev University, Kazakhstan, awarded through a highly competitive selection process.

Research didn’t pause while he worked. At ABUTH, Musa evaluated the quality of services and the everyday processes that either support or undermine safety. As a senior-led investigator, he assessed the legibility of handwritten prescriptions—work published in Innovations in Pharmacy, the institutional journal of the University of Minnesota College of Pharmacy. The study found moderate legibility, frequent omission of key patient details, and a troubling rate of medication errors among prescribers. “We emphasized the importance of interventions, including the introduction of electronic prescriptions to improve communication between prescribers and pharmacists. This system could also enhance clarity, reduce errors, and improve patient safety, which has been implemented in some departments or units ABUTH.”

He also collaborated on studies that confronted workforce and systems challenges head-on: “Exploring Nigerian pharmacists’ attitudes and perceptions to continuing education and professional development; Evaluation of job satisfaction among pharmacists working in public health facilities; Global neurosurgical challenges: a focus on central Asia,” among others. The thread through these projects is practical: in low- and middle-income countries, pharmacists are often the most accessible health professionals; understanding their training needs, job satisfaction, and working conditions isn’t academic bookkeeping—it’s a patient-safety strategy.

Global impact—and a focus on translation

Recognition has followed the work. Musa earned the international scholarship to Nazarbayev University for his MPH, received a Rackham Graduate Fellowship and other merit awards, and is now a PhD scholar in the Clinical Pharmacy Translational Sciences program at the University of Michigan’s College of Pharmacy. His research centers on pharmacogenomics and health-services science, with an eye toward policies and practices that scale.

“My goal,” he emphasized, “is to strengthen health systems everywhere, so that population health is advanced not just for those with privilege, but for every patient, family, and community.”

The implications are concrete. Musa points to findings on prescription legibility and missing patient details, to workforce studies in Nigeria, and to his COVID-19 nanotechnology reviews as examples of research that pushes directly into practice and policy. “My significant contribution was at ABUTH, where our study identified errors in 38% of handwritten prescriptions. If electronic prescribing reduces these errors by a conservative 60%, that’s approximately 2,280 errors avoided per 10,000 prescriptions—likely preventing between 5 and 10 deaths annually and sparing thousands from harm. The financial benefits are substantial as well: preventing downstream costs of adverse drug events (often ₦50,000–₦150,000 per case) could save roughly $75,000–$225,000 per 10,000 prescriptions at current rates (≈₦1,535 to $1).

He extends the logic of precision timing in medicines to chronic-disease care. “If oral chronopharmaceutical drug delivery were widely adopted, it could greatly improve treatment adherence and outcomes for chronic conditions like hypertension, which affects over 1 billion people worldwide. Studies indicate that aligning medication with the body’s circadian rhythm can decrease adverse effects and hospitalizations by up to 20%. In Nigeria alone, where cardiovascular-related hospital stays can cost ₦50,000 to ₦200,000 per patient, this innovation could save millions of naira each year in healthcare expenses and prevent thousands of complications,” Dr. Musa explained. Adding that, globally, even a small 10% drop in hospitalizations could save healthcare systems billions of dollars annually.

The same translational instinct guided his pandemic work. If more people had access to “nanosensor-based diagnostics and advanced nanofiber PPE,” he argues, transmission and hospitalizations could be sharply reduced. “In fact, this approach could cut transmission and hospitalization rates by around 15–20%. To put this into perspective, Nigeria spent over $325 million (about ₦500 billion) on pandemic response during COVID-19. Even a 10% reduction in hospitalizations and severe cases through early detection and better PPE could save tens of millions of dollars and thousands of lives. Worldwide, solutions powered by nanotechnology like these could prevent millions of infections and save healthcare systems billions of dollars every year.”

The larger lesson

Across settings and disciplines, Musa’s path underscores a broader shift: the pharmacist as clinician, investigator, systems thinker, and advocate. From chronotherapeutic tablets to the case for electronic prescribing, from nanomedicine to workforce reform, his work ties scientific insight to policy-relevant action. In an era when health systems are strained by chronic disease, demographic change, and periodic shocks, that combination—ground-level realism and translational ambition—may be as important as any single breakthrough.